Analysis of functional data from Duchenne participants in a natural history study and the placebo control arm of an interventional clinical trial for the treatment of Duchenne in combination with other natural history data sets.

Duchenne muscular dystrophy (DMD) is a rare, inherited disorder that causes progressive muscle weakness, typically beginning in early childhood. It primarily affects boys and leads to loss of the ability to walk, breathing difficulties, and heart problems. Currently, there is no cure for DMD, and available treatments only slow the progression of the disease. Because of this, new treatment options are urgently needed.

This research will support a clinical trial (NCT05693142) testing a new gene therapy designed to treat DMD. Instead of using a traditional control group where some participants receive a placebo (a non-active treatment), researchers will use existing “natural history” data for comparison to our treated group with the goal of showing treatment effect of our drug. Natural history data includes information collected over time about how DMD progresses in patients who are not receiving the new therapy.

This method of comparison to an external control group is being used because it would be unethical to deny participants access to current treatments that might help them. Also, since gene therapy can cause visible physical changes, it would be difficult to keep patients and doctors unaware of who received the real treatment (a process called “blinding”). Using natural history data allows researchers to compare treated patients with untreated ones fairly and safely. This approach will help determine whether the gene therapy improves symptoms and slows the disease, which could lead to better treatment options for people with DMD.